In this group of dogs, the range of clinical signs is not significantly different between small and large breeds. The prevalences of clinical and clinicopathological findings

appears to be similar to those historically reported. Dogs with more clinical signs tend to have higher ALT and ALP activities.

Canine HbA1c: validation of an immunoturbidimetric assay and determination of a reference interval

Anne Florentine Goemans, Ian Ramsey

University of Glasgow, Glasgow, UK

BACKGROUND

Haemoglobin A1c (HbA1c), provides a reliable measure of glycaemic control over 2 to 3 months in human diabetics. In dogs, formation of HbA1c has been demonstrated; but currently no commercial assays exist for determining canine HbA1c. The validation of such an assay could have significant benefits for the management of canine diabetes.

OBJECTIVE

To validate a commercially available automated immunoturbidimetric assay for canine HbA1c and determine a reference interval for canine HbA1c in a normoglycaemic hospital population.

METHODS

The specificity of the assay was assessed by inducing HbA1c in vitro using isolated canine haemoglobin preparations. Imprecision was assessed using manufacturer supplied

control materials for between run imprecision. The linearity was assessed by mixing known samples in differing proportions and the effect of anticoagulants by taking paired samples. 7 Samples with known lipid concentrations, triglycerides from 0.68–25.58 mmol/L and cholesterol from 4.9–11.7 mmol/L were measured before and after removal of serum and replacement with 0.9% saline. The effect of haemolysis was also determined. A reference interval and the effect of age and breed predisposition was determined using EDTA whole blood samples from 60 normoglycaemic non-anaemic hospitalised animals. Measured values were expressed in terms of mmol of HbA1c per mol of haemoglobin.

RESULTS

HbA1c increased proportionally with glucose concentration in vitro. The between run imprecision was 5.9% (3% and 8.8%). The assay was linear within the expected working range. EDTA and heparin can be used interchangeably for HbA1c measurement. Measured HbA1c concentrations were affected by moderate to severe lipaemia and by haemolysis. The reference interval for HbA1c was 9–18.5 mmol/mol, with a mean of 14.3 mmol/mol HbA1c and a range of 9 to 19 mmol/mol. There was no apparent effect of age or breed on HbA1c concentration.

CONCLUSIONS

The assay evaluated provides a reliable method of canine HbA1c measurement with good analytical performance. Further work to assess the effect of interference from lipaemia and haemolysis is needed.

HbA1c measurements in canine diabetic patients compared to normoglycaemic controls and fructosamine measurements.

Susanna Spence, Floortje Goemans, Aimee Hope, Ian Ramsey

University of Glasgow, Glasgow, UK

BACKGROUND

Diabetes mellitus is a common endocrinopathy in small animal medicine yet complications such as diabetic ketoacidosis and cataracts frequently arise. Fructosamine levels and glucose curves are often used to evaluate insulin therapy in dogs but they are not without their limitations. In contrast, in human medicine, measurement of HbA1c (a form of glycosylated haemoglobin) is used to monitor diabetic stability by providing an indication of glycaemic control over the preceding 2 to 3 months. Moreover HbA1c concentrations are

associated with outcome in human diabetes, whereas fructosamine values are not. Recently, the Siemens DCA Vantage® analyser has been demonstrated to measure HbA1c reliably and repeatedly in canine patients and a reference range has been identified.

OBJECTIVE

To compare HbA1c measurements in diabetic and non-diabetic patients within a hospital population and to determine the relationship between HbA1c and fructosamine levels in diabetic patients.

METHODS

HbA1c was measured from EDTA samples using the Siemens DCA Vantage® analyser. Three groups were included in this study: an uncontrolled diabetic group (Group 1, n=26; which included 3 patients with concurrent hyperadrenocorticism); a normoglycaemic control group (Group 2, n=76); and a normoglycaemic group with hyperadrenocorticism (Group 3, n=5). All groups were age matched. Group 1 was